State Street Corporation has disclosed a significant stake in Geron Corp, according to a recent filing. The firm now holds approximately 5% of the common stock of the pharmaceutical company, amounting to over 31.8 million shares. This investment reflects growing institutional interest in Geron, which is involved in the development of innovative therapies for cancer.
Geron Corp, based in Menlo Park, California, specializes in pharmaceutical preparations, as classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker symbol GERN. The recent filing was made on November 10, 2026, and is part of a series of disclosures by Geron, including a quarterly report filed just days earlier.
The Schedule 13G filing indicates that State Street Corporation has shared voting power over 30,180,644 shares and shared dispositive power over 31,896,515 shares. This level of ownership suggests that State Street is positioning itself as a significant player in Geron’s future, potentially influencing company decisions and strategies.
This development may affect various stakeholders, including shareholders, management, and competitors within the pharmaceutical industry. As institutional investors like State Street increase their stakes, it may lead to heightened scrutiny and expectations regarding Geron’s performance and strategic direction.
The filing does not specify what actions might follow this significant investment, leaving the market to speculate on the implications for Geron Corp and its operations in the competitive pharmaceutical landscape.
Read Next
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction
Orchestra BioMed CFO Acquires Shares in Recent Filing
Upwork CFO Erica Gessert Reports Major Stock Transactions




